Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01453582
Other study ID # FJ2011-1.1
Secondary ID
Status Completed
Phase Phase 3
First received October 13, 2011
Last updated February 6, 2018
Start date December 2011
Est. completion date September 2015

Study information

Verified date December 2017
Source Shanghai Greenvalley Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to confirm the efficacy and safety of total flavonoids of propolis dropping pill to treat angina pectoris, evaluated by total exercise time of treadmill exercise test.


Recruitment information / eligibility

Status Completed
Enrollment 478
Est. completion date September 2015
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender All
Age group 35 Years to 70 Years
Eligibility Inclusion Criteria:

- Class I, Class II and Class III stable angina pectoris, angina attack more than 3 times one week;

- Qi deficiency and blood stasis syndrome of Traditional Chinese Medicine;

- In resting electrocardiogram, ST-segment deviation=0.05mv and/or T-wave inversion=0.2mv in the leads R-wave is predominant during non-attack period, or ST-segment deviation=0.1mv and/or T-wave inversion=0.2mv in the leads R-wave is predominant during angina attack;

- Total exercise time of treadmill exercise test=3 minutes.The discontinuance standard should be reached. And the difference of total exercise time between before and after run in period should =15%;

- Other confirmed diagnostic evidence of coronary heart disease, such as definite history of old myocardial infarction, or incomplete revascularization one year after coronary intervention therapy(residual luminal stenosis=50%), or coronary angiography evidence(at least single vessel disease and luminal stenosis=50%), or nuclein examination evidence, or computer tomography angiography evidence;

- Signed the informed consent form.

Exclusion Criteria:

- Chest pain caused by acute myocardial infarction(AMI), Class IV/serious angina pectoris, psychosis, serious neurosis, climacteric syndrome, hyperthyroidism, Cervical Spondylosis, gallbladder- heart syndrome, gastroesophageal reflux, hiatus hernia, aortic dissection, aortic valve disease;

- Not well controlled hypertension(systolic pressure=160mmHg,diastolic pressure=100mmHg), serious cardiopulmonary insufficiency, serious arrhythmia(rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc);

- Serious diseases of heart, lung, liver, kidney and blood;

- Allergic constitution or allergic to the components of total Flavonoids of Propolis dropping pill;

- Women during pregnancy or lactation;

- Received any major operation within 4 weeks;

- Have been in other clinical trials within 30 days;

- Using but can not withdraw anti-angina medicine as long acting nitrates;

- Not well controlled hyperglycemia;

- Not fit for this trial judged by investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Total Flavonoids of Propolis dropping pill
One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
total Flavonoids of Propolis dropping pill
One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.

Locations

Country Name City State
China The Affiliated Hospital to Changchun University of Chinese Medicine Changchun Jilin
China Guangdong Second Provincial Traditional Chinese Medicine Hospital Guangzhou Guangdong
China Neimenggu Hospital of Traditional Chinese and Mongolian Medicine Huhehaote Neimenggu
China Ruikang Hospital of Guangxi Traditional Chinese Medical University Nanning Guangxi
China Shanghai Hospital of Traditional Chinese Medicine Shanghai Shanghai
China Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai Shanghai
China Affiliated Hospital of Liaoning University of Traditional Chinese Medicine Shenyang Liaoning
China Sencond Affiliated Hospital of Liaoning University of Traditional Chinese Medicine Shenyang Liaoning
China Shanxi Hospital of Traditional Chinese Medicine Taiyuan Shanxi
China First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine Tianjin Tianjin
China Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine Tianjin Tianjin
China Hubei Hospital of Traditional Chinese Medicine Wuhan Hubei
China Xinjiang Hospital of Traditional Chinese Medicine Wulumuqi Xinjiang

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Greenvalley Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of total exercise time of treadmill exercise test -2 week, 0 weeks, 12 weeks
Secondary The marked effective rate of angina pectoris Class I: No symptom or almost no symptom, decrease of angina pectoris total score = 1/3;
Class II: No symptom or almost no symptom, decrease of angina pectoris total score = 2/3;
Class III: Almost no symptom, decrease of angina pectoris total score = 2/3, or the score decrease to the degree of Slight or Class I.
-2 weeks, 0 week, 6 weeks, 12 weeks
Secondary Attack times of angina pectoris -2 weeks, 0 week, 6 weeks, 12 weeks
Secondary Pain degree of angina pectoris -2 weeks, 0 week, 12 weeks
Secondary Duration of angina pectoris attack -2 weeks, 0 week, 6 weeks, 12 weeks
Secondary Dose change of nitroglycerin Withdraw: completely withdrawal after the treatment;
Decrease: decrement =50% after the treatment;
No change: decrement <50% after the treatment.
-2 weeks, 0 week, 6 weeks, 12 weeks
Secondary The main symptoms of Chinese Traditional Medicine Effect index = (total score before treatment - total score after treatment)/total score before treatment×100%
Cured: effect index =90%;
Marked effective: 90%> effect index =70%;
Effective: 70%> effect index =30%;
Ineffective: effect index <30%.
-2 weeks, 0 week, 6 weeks, 12 weeks
Secondary Score change of the Seattle Angina Questionnaire (SAQ) 0 week, 12 weeks
Secondary Improvement of ECG Cured: normal or almost normal;
Marked effective: ST-segment deviation upturn=0.05mV, but still abnormal, improvement of T-wave inversion of main leads =25%, or flate T-wave change to vertical, improved atrioventricular block or intraventricular block;
Effective: almost no charge;
Ineffective: anabatic ST-segment deviation, deeper T-wave, or flate T-wave change to inverted.
-2 weeks, 0 week, 12 weeks
Secondary Improvement of other indexes of treadmill exercise test metabolic equivalent, blood pressure, oxygen consumption, speed, grade. -2 weeks, 0 week, 12 weeks
Secondary Time to ST-segment deviation>1mm and positive symptoms appear -2 weeks, 0 week, 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT01257282 - Prevalence and Prognostic Value of Unrecognized Myocardial Injury in Stable Coronary Artery Disease (PUMI) N/A
Completed NCT02294942 - Extended-Release RANCAD in the Patients With Stable Angina Pectoris Phase 3
Completed NCT02029118 - Acupoint Application in Patients With Stable Angina Pectoris (AASAP) Early Phase 1
Completed NCT00763464 - Coronary Artery Disease (CAD) in Postmenopausal Women N/A
Recruiting NCT02328898 - Randomized "All-comer" Evaluation of a Permanent Polymer Resolute Integrity Stent Versus a Polymer Free Cre8 Stent Phase 4
Completed NCT02339454 - Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris Phase 3
Completed NCT01502943 - Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index Phase 4
Terminated NCT00638326 - Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity Phase 3
Withdrawn NCT02165670 - BASIC VALIDATE Coronary Stent Registry
Completed NCT01632371 - Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4 Phase 4
Completed NCT01363661 - Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris Phase 4
Completed NCT01293097 - Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI Phase 4
Completed NCT02747329 - A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT N/A
Recruiting NCT05347069 - Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization Phase 4
Recruiting NCT04938661 - Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE) N/A
Not yet recruiting NCT03155971 - PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial) N/A
Active, not recruiting NCT02285322 - Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study N/A
Active, not recruiting NCT02062021 - Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease N/A
Active, not recruiting NCT01937065 - Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study N/A
Active, not recruiting NCT01947361 - Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber) N/A